The design of the study included a 12-week screening period to exclude pseudo-resistant hypertension by changing all patients to a standardized single-pill triple-therapy (amlodipine, valsartan, ...

The 4,822-patient study missed statistical significance for a composite primary endpoint of reducing cardiovascular death and total heart failure hospitalisations by 13% compared with valsartan ...